As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...
A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...
As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...
Corcept Therapeutics is upgraded to Buy after a patent loss and FDA setback, with focus shifting to relacorilant in oncology.
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...
Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more
The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV ...
The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for ...
Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.
Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s ABBV combination treatment for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results